From the Journals

Higher odds for preterm, C-section births seen in women with PsA


 

Are adverse outcomes linked to disease activity or treatment?

Patients in the study had a higher risk of adverse outcomes when they had a PsA diagnosis, and when they received antirheumatic treatment – but were the adverse outcomes associated with a patient’s high disease activity or need for antirheumatic treatment?

“Our interpretation is that a PsA disease that requires continued antirheumatic treatment during pregnancy is more severe than PsA that does not require treatment,” Dr. Remaeus and colleagues write. “Thus, the increased risk of adverse outcomes in pregnancies with maternal antirheumatic treatment is probably attributed to disease severity rather than an effect of the medication itself.”

Dr. Anja Strangfeld of the German Rheumatism Research Center, Berlin

Dr. Anja Strangfeld

Anja Strangfeld, MD, PhD, of the German Rheumatism Research Centre in Berlin, told this news organization that the results of the study are important because it is one of the first to report differences in risk in pregnancy outcomes for women with and without PsA.

“The information is relevant to guide rheumatologists in advising patients with PsA when planning the first or subsequent pregnancies,” she said. “The results are reassuring in reporting that the elevated risk for PsA patients for adverse pregnancy outcomes is low in patients not in need of antirheumatic medication, presumably in low-disease activity.”

However, the study is still unclear on whether the association with adverse pregnancy outcomes in patients is the result of higher disease activity or the need for antirheumatic treatment, she explained.

“It was only hypothesized that those patients under bDMARD treatment are/were in high disease activity. There [is] no information on disease activity in the data sources, which limits the results,” she said. “The investigation still does not solve the important question – if adverse pregnancy outcomes are rather related to high disease activity or the medication to treat this situation.”

There was no specific funding for this study. The study authors and Dr. Strangfeld have disclosed no relevant financial relationships.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

More severe psoriasis linked to an increased risk of PsA
MDedge Rheumatology
Clinical Edge Journal Scan Commentary: PsA October 2021
MDedge Rheumatology
Acceptance of biosimilars grows but greater use may hinge on switching, interchangeability studies
MDedge Rheumatology
First-in-class TYK inhibitor shows durable effect for psoriasis
MDedge Rheumatology
Study of biologics’ impact on psoriasis-to-PsA transition contradicts previous findings
MDedge Rheumatology
Adalimumab biosimilar Cyltezo gets interchangeability designation
MDedge Rheumatology
Few JAK inhibitor users have diminished immune response to COVID-19 vaccines
MDedge Rheumatology
U.S. arthritis prevalence continues steady rise; activity limitations grow more rapidly
MDedge Rheumatology
Tramadol linked to higher risk of mortality, compared with codeine
MDedge Rheumatology
Better COVID-19 outcomes confirmed in TNF inhibitor users
MDedge Rheumatology